InkVivo
Swiss biotech spin-off from ETH Zurich, addresses a critical challenge in drug development: improving how medicines are formulated and delivered to enhance efficacy and patient outcomes. Its proprietary polymer platform enables faster formulation optimization and more precise delivery of oral and long-acting injectable drugs.
InkVivo has raised €1.2M across 1 funding round from 3 investors, most recently a Pre-Seed round in Aug 2025. Based in Zurich, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Zurich, Switzerlandinkvivo.tech ↗
Total raised
€1.2M
€1,169,093
Funding rounds
1
Investors
3
distinct backers
Active since
2025-08
latest 2025-08
Funding by year
EUR raised per yearInkVivo — funding by year — interactive chart.
Data table
| InkVivo — funding by year | |
|---|---|
| 2025 | €1.2M |
Signals
High confidenceRaise-next likelihood34
base rate 24% for Pre-Seed
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-08-13 | Pre-Seed | €1.2M | Business Angels,Claves Investments,TiVentures | View deal → |
Investors
3Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData